🇪🇺 MANGAFODIPIR in European Union

EMA authorised MANGAFODIPIR on 22 May 1997

Marketing authorisation

EMA — authorised 22 May 1997

  • Application: EMEA/H/C/000137
  • Marketing authorisation holder: GE Healthcare AS
  • Local brand name: Teslascan
  • Indication: This medicinal product is for diagnostic use only. Contrast medium for diagnostic magnetic resonance imaging (MRI) for the detection of lesions of the liver suspected to be due to metastatic disease or hepatocellular carcinomas. As an adjunct to MRI to aid in the investigation of focal pancreatic lesions.
  • Status: withdrawn

Read official source →

MANGAFODIPIR in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Gastroenterology approved in European Union

Frequently asked questions

Is MANGAFODIPIR approved in European Union?

Yes. EMA authorised it on 22 May 1997.

Who is the marketing authorisation holder for MANGAFODIPIR in European Union?

GE Healthcare AS holds the EU marketing authorisation.